Incytevs.Regeneron
INCY vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 3.4× larger than Incyte by market cap; Incyte trades at the lower P/E (15.1 vs 19.0); year to date, Incyte leads (+29.6% vs +7.3%).
Side by side
| INCY | REGN | |
|---|---|---|
| Market cap | $24.4B | $82.2B |
| Price | $129.72 | $833.56 |
| Today | +1.4% | +0.6% |
| Return YTD | +29.6% | +7.3% |
| Return 1Y | +50.5% | +40.5% |
| P/E | 15.1 | 19.0 |
| P/S | 4.2 | 5.3 |
| P/B | 3.8 | 2.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More INCY & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.
See where INCY and REGN sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →